ReviewJournal of fungi (Basel, Switzerland)2020
Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway.
Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Compound Z247611722 Exhibits Antifungal Activity by Inhibiting Serine Palmitoyltransferase.Nature communications · 2026Article
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- Functional and Biochemical Characterization of Spermidine Synthase CauSpe3 fromPathogens (Basel, Switzerland) · 2026Article
- Evolutionary diversity of sphingolipid metabolism proteins in fungi.IMA fungus · 2026Article
- Design, synthesis and SAR studies of N'-(Ethynylsalicylidene)arenecarbohydrazides as next-generation broad-spectrum antifungal agents.Bioorganic & medicinal chemistry · 2025Article
- Targeting ceramide synthases for the development of new antifungals.Structure (London, England : 1993) · 2025Article
- In vitro and in vivo antifungal activity of Minocycline albumin nanoparticles in combination with fluconazole against azole-resistant Candida spp.BMC microbiology · 2025Article
- Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.npj antimicrobials and resistance · 2025Review
- The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders.Frontiers in pharmacology · 2025Review
- Antifungal Activity of Disalt of Epipyrone A fromJournal of fungi (Basel, Switzerland) · 2024Article
- Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action.Antibiotics (Basel, Switzerland) · 2023Review
- Metabolic Features of a NovelMetabolites · 2023Article
- Genetic Characterization of the Acidic and Neutral Glycosphingolipid Biosynthetic Pathways inMicroorganisms · 2023Article
- An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.Expert opinion on pharmacotherapy · 2023Review
- Deciphering the Role of PIG1 and DHN-Melanin inJournal of fungi (Basel, Switzerland) · 2023Article
- Comprehensive genome-scale metabolic model of the human pathogenFrontiers in bioinformatics · 2023Article
- Chromosome 1 trisomy confers resistance to aureobasidin A inFrontiers in microbiology · 2023Article
- Access to Anti-Biofilm Compounds from Endolichenic Fungi Using a Bioguided Networking Screening.Journal of fungi (Basel, Switzerland) · 2022Article
- Vaccine protection by Cryptococcus neoformans Δsgl1 is mediated by γδ T cells via TLR2 signaling.Mucosal immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs. There has been a significant increase in the development of antifungal compounds with a similar mechanism of action of current drugs. In contrast, there has been very little progress in developing compounds inhibiting totally new fungal targets or/and fungal pathways. This review focuses on novel compounds recently discovered to target the fungal sphingolipids and their metabolizing enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.